Related Experiment Video

Updated: Aug 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Pathogenesis-oriented targets for adjunctive therapy

Otelo Rigato1, Eliezer Silva, Reinaldo Salomao

  • 1Immunology Laboratory, Division of Infectious Diseases, Universidade Federal de Sao Paulo, CEP 04039-032, Sao Paulo, SP, Brazil.

Endocrine, Metabolic & Immune Disorders Drug Targets
|June 22, 2006
PubMed

Insights

Despite effective antimicrobial treatments, sepsis mortality remains high. This review explores novel adjunctive sepsis therapies targeting the underlying pathophysiology, offering hope for improved patient survival rates.

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Pathophysiology

Background:

  • Sepsis outcomes are multifactorial, involving host and microbial factors.
  • Mortality persists despite adequate antimicrobial therapy, necessitating further research.
  • Recent advances in understanding sepsis pathophysiology offer new therapeutic avenues.

Purpose of the Study:

  • To review sepsis pathogenesis.
  • To identify potential targets for adjunctive sepsis therapies.
  • To comment on clinical trials and experimental data for these therapies.

Main Methods:

  • Literature review of published clinical trials.
  • Analysis of experimental data supporting adjunctive therapies.
  • Discussion of pathogenic-oriented therapeutic targets.

Main Results:

  • Adjunctive sepsis therapies have not yet consistently improved survival rates.
  • Significant progress in understanding sepsis pathophysiology has been made.
  • Identified potential adjunctive therapies include fluid replacement, glucose control, corticosteroids, mechanical ventilation, and activated protein C.

Conclusions:

  • Despite challenges, new effective sepsis treatments are plausible.
  • Targeting sepsis pathophysiology offers promising avenues for adjunctive therapy.
  • Further research and clinical trials are warranted to validate novel interventions.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...